Sanhuang Xiexin Decoction Ameliorates TNBC By Modulating JAK2-STAT3 and Lipid Metabolism.
10.1007/s11655-023-3555-x
- Author:
Ying QI
1
;
Xin-Jie WU
1
;
Jing-Bin SHI
2
;
Xiao-Wei SHI
2
;
Na ZHAO
2
;
Yang XIONG
2
;
Li-Pei WANG
3
,
4
Author Information
1. School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, 311121, China.
2. Zhejiang Chinese Medical University, Hangzhou, 310053, China.
3. School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, 311121, China. Wanglipei_zju@
4. com.
- Publication Type:Journal Article
- Keywords:
Janus kinase 2-signal transducer and activator of transcription 3;
Sanhuang Xiexin Decoction;
epithelial-mesenchymal transition;
lipid metabolism;
triple-negative breast cancer
- MeSH:
Animals;
STAT3 Transcription Factor/metabolism*;
Drugs, Chinese Herbal/pharmacology*;
Janus Kinase 2/metabolism*;
Lipid Metabolism/drug effects*;
Female;
Mice, Inbred BALB C;
Triple Negative Breast Neoplasms/metabolism*;
Cell Line, Tumor;
Epithelial-Mesenchymal Transition/drug effects*;
Signal Transduction/drug effects*;
Mice
- From:
Chinese journal of integrative medicine
2024;30(12):1080-1089
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the therapeutic effect of Sanhuang Xiexin Decoction (SXD) on triple-negative breast cancer (TNBC) in mice and its underlying mechanism.
METHODS:The high-performance liquid chromatography (HPLC) was used to quantitate and qualify SXD. A total of 15 female BALB/c mice were inoculated subcutaneously on the right hypogastrium with 3×105 of 4T1-Luc cells to establish TNBC mouse model. All mice were divided randomly into 3 groups, including phosphate buffered solution (PBS), SXD and doxorubicin (DOX) groups (positive drug). Additionally, tumor growth, pathological changes, serum lipid profiles, expression of Janus kinase 2 (JAK2)-signal transducer and activator of transcription 3 (STAT3) signaling pathway and its key targets including inflammatory factors, cell cycle and epithelial-mesenchymal transition (EMT) markers were investigated. Besides, the biosafety of SXD was also evaluated in mice.
RESULTS:Rhein, coptisine, berberine hydrochloride and baicalin were all found in SXD, and the concentrations of these 4 components were 0.57, 2.61, 2.93, and 46.04 mg/g, respectively. The mouse experiment showed that SXD could notably suppress the development of tumors and reduce the density of tumor cells (P<0.01). The serum lipid analysis and Oil-Red-O staining both showed the differences, SXD group exhibited higher serum adiponectin and HDL-C levels with lower TC and LDL-C levels compared to the PBS and DOX groups (P<0.05 or P<0.01), respectively. SXD also decreased the levels of phospho-JAK2 (p-JAK2), phospho-STAT3 (p-STAT3) expressions and its downstream factors, including mostly inflammatory cytokine, EMT markers, S phase of tumor cells and vascular endothelial growth factor (VEGF) expression (P<0.05 or P<0.01), respectively. The biosafety assessment of SXD revealed low levels of toxicity in mice.
CONCLUSION:SXD could inhibit TNBC by suppressing JAK2-STAT3 phosphorylation which may be associated with modulation of lipid metabolism.
